Site growth

Independent research site vs joining a site network

By TrialNotice · Updated
Drone view of a standalone single story medical office building in a leafy suburb at golden hour
Short answerJoining a site network brings centralized contracting, sponsor relationships, and shared recruitment resources, in exchange for control and a share of revenue. Staying independent keeps control but means building your own sponsor relationships and patient pipeline. Consolidation is accelerating, with private equity backed platforms acquiring independent sites, so independents compete best on specialization, speed, and patient access they own.

How did site consolidation develop?

For years, most research sites were independent practices. Over the last several years, networks have grown through acquisitions. Velocity Clinical Research acquired Meridian Clinical Research in December 2022 to create a network of roughly 80 wholly owned sites, BayPine acquired CenExel Clinical Research in April 2025, and THL Partners acquired Headlands Research in August 2025. Strategic acquirers accounted for nearly 90% of site related deals between 2021 and mid 2025, with private equity sponsors increasingly active (Objective IBV).

The trend has critics. A private equity watchdog has raised concerns about how consolidation of sites and ethics review boards could affect trial safety, patients, and costs (Private Equity Stakeholder Project).

What does a network offer?

  • Centralized contracting, budgeting, and regulatory support.
  • Existing sponsor and CRO relationships, and visibility for more studies.
  • Shared recruitment resources and marketing.
  • Capital for facilities and staff.

What does a site give up?

  • Control over which studies to take and how to run them.
  • A share of revenue, or ownership if acquired.
  • Some independence in local relationships and branding.

How can an independent site compete?

  • Speed. Physician practices reached first patient in fastest in Tufts CSDD's startup benchmarks (Applied Clinical Trials), an advantage networks must work to match.
  • Repeat relationships. Familiar sites finish startup 9.9 weeks faster (Tufts CSDD). Deliver on each study and sponsors come back.
  • Specialization. Be the site sponsors think of for one therapeutic area.
  • Patient access you own. A local physician referral network is something an acquirer values and a sponsor can verify. Physicians refer less than 0.2% of their patients today (Tufts CSDD), so the room to grow is large.

What should you ask before joining a network?

  1. How are studies allocated among network sites?
  2. What revenue share or fees apply?
  3. Who controls your patient relationships and data?
  4. What recruitment support is actually provided, and how is it measured?

Related: how to grow a clinical research site.

Get your study in front of the right local physicians

TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.

Talk to TrialNotice

Sources

  1. Objective Investment Banking and Valuation, "Valuation of Clinical Research Sites: What Buyers Look For"
  2. Private Equity Stakeholder Project, "Private equity moves into clinical trials" (November 2025)
  3. Applied Clinical Trials, "New Benchmarks for Trial Initiation Activities" (Tufts CSDD)
  4. Tufts CSDD, first comprehensive clinical site initiation benchmark (2018), via GlobeNewswire
  5. Applied Clinical Trials, "Tufts CSDD Study Explores Low Recruitment Rates"

Keep reading

Two clinical research site staff members reviewing a growth plan together in a bright office
Site growth

How to grow a clinical research site: a practical playbook

Research sites grow by building a record sponsors can verify: enrollment, startup speed, and screen failure. Here is what the data says about site growth, why sponsors reuse sites, and a six step playbook.

 Research site director presenting enrollment results to sponsor representatives across a conference table
Site growth

How research sites get more studies from sponsors and CROs

Sponsors award more studies to sites that enroll reliably, start fast, and forecast honestly. Here is how sponsors choose, why new sites face a slower path, and what a site can do to win repeat work.

 Sponsor clinical operations team reviewing site maps and performance charts on a large screen
Site growth

How sponsors and CROs select clinical trial sites

Sponsors shortlist sites with historical data and epidemiology, send feasibility questionnaires, then choose on patient access, past enrollment, and startup speed. Here is the process, how it evolved, and what it means for sites.